- Barrons.com•1 hour ago
Amgen (AMGN:Nasdaq) By Credit Suisse ($170.68, July 28, 2016) We raise our 2016, 2017 and 2018 earnings-per-share estimates for Amgen to $11.38, $12.64 and $13.39, respectively, from $11.14, $12.10 and $12.91. Neulasta biosimilar competition is likely delayed pushing it later into 2017.
- Forbes•16 hours ago
Second-quarter earnings season has been going for more than a week, and we’ve had a chance to hear from all four of the biggest companies in biotech as measured by sales, market valuation and clout. Here’s what they had to say in their business updates, along with some commentary from analysts
After hours: 171.20-0.08 (-0.05%) as of 7:55 PM EDT
|Bid||168.53 x 100|
|Ask||172.87 x 100|
|52wk Range||130.09 - 181.81|
|Day's Range||166.52 - 171.80|
|Avg Vol (3m)||2,889,806|
As of 4:00 PM EDT. Market closed.